Presentations
Maanen E.M.T., Steeg, TJ.v., Kalinina J., Stone, J., Michener M.S., Savage M.J., Parker E.M., Danhof, M. Resilience in the Amyloid Precursor Protein ( APP ) pathway revealed by systems pharmacology modeling following β – and γ -secretase inhibition. AAIC, 2017.
Schulthess P., Post T.M., Yates J., Graaf H.J.v.d. Frequency-domain response analysis for quantitative systems pharmacology models. PAGE, 2017. [Link to publication]
Vis P., Snelder N., Ahsman M., MacLean D. and Faessel H., Optimization of trial design and dose selection based on the quantitative assessement of the efficacy of TAK-385. WCOP, (2016).
Snelder N. and Steeg T.v., QSP Modelling at the heart of the action. ACoP, (2016).
Maanen E.v., Steeg T.v., Savage M.J., Michener M.S., Stone J. and Danhof M., Quantification of the modulation of the Aβ oligomers following secretase inhibition; A systems pharmacology approach. Computational Hub Meeting.(2016)
Maanen E.v., Steeg T.v., Kalinina J., Stone J., Michener M.S., Savage M.J., Parker E.M. and Danhof M. (2016). Quantification of the modulation of Aβ oligomers following secretase inhibition- A systems pharmacology approach. ACOP (2016)
Snelder N., Drenth H., Bergmann K., Wood N., Hibberd M. and Scott G., PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin. What is the optimal testosterone level?, PAGE.(2015) [Link to publication]
Bosch R., K.Bergmann, Baverel P., Fairman D., Vis P. and Agoram B., A mechanism-based model is able to simultaneously explain the effect of rhLCAT and HDL mimetics on biomarkers of reverse cholesterol transport. PAGE.(2015) [Link to publication]
Bosch R., Gao W., Vargo R., Baliathan C., Fancourt C., Kothare P.A., Kjellson M.C., Karlsson M. and Post T., Application of a Semi-Mechanistic, Integrated Glucose-Insulin Model to Graded Glucose Infusion Placebo Data to translate Glucose Insulin dynamics between Healthy Humans and Non-Human Primates. PAGE.(2015) [Link to publication]
Recombinant Antithrombin (ATryn) to achieve >80% AT activity in pediatric and neonatal ECMO patients
DeJongh J., Streisand J., Todd Tzanetos D., Fanning J. and Drenth H., Recombinant Antithrombin (ATryn) to achieve >80% AT activity in pediatric and neonatal ECMO patients. 26th Annual ELSO Conference.(2015) [Link to publication]